Figure 1. Summary of anti-cancer treatments, patterns of failures, and the acquisition timings of brain magnetic resonance images.

The figure shows (A) the treatment progress (in years) mainly until the diagnosis of BMs, (B) the treatment progress (in months) after the BM diagnosis, (C) the schedule (in days) for EBRT for BMs, and (D) the biologically effective doses of the EBRT.

*EBRT: conventional 3D-CRT in 56 Gy/28 fr for enhancing the locoregional disease control including the supraclavicular lymph node metastases.

**The WBRT and SRS were performed over 15 days and seven days, including five days off and two days off, respectively.

***pRT: palliative 3D-CRT with 20 Gy/5 fr for the chest wall recurrence refractory to chemotherapy.

BMs: brain metastases; EBRT: external beam radiotherapy; 3D-CRT: three-dimensional conformal radiotherapy; rN: regional lymph node recurrence; SCLN: supraclavicular lymph nodes; PD: progression; IP: interpectoral (Rotter) LN; OSS: bone metastasis; LR: local recurrence; LYM: distant lymph node metastases; ADR: adrenal metastasis; PLE: pleural metastases/dissemination; Bt: mastectomy; ZOL: goserelin; TAM: tamoxifen; ANA: anastrozole; FUL: fulvestrant; EXE: exemestane; EVE: everolimus; LET: letrozole; PAL: palbociclib; EC: epirubicin+cyclophosphamide (CPA); DTX: docetaxel; MRI: magnetic resonance imaging; WBRT: whole-brain radiotherapy; SRS: stereotactic radiosurgery; PER: peritoneal dissemination; HEP: liver metastases; ERI: eribulin; PTX: paclitaxel; BEV: bevacizumab; pRT: palliative radiotherapy; Cape: capecitabine; fr: fractions; BED_10/2 : a biologically effective dose based on the linear-quadratic model with an alpha/beta ratio of 10/2